ArticleWorld journal of gastrointestinal oncology2025
Contrast-enhanced ultrasound in evaluating the curative effect of interventional therapy in patients with liver cancer.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast-enhanced ultrasonography (CEUS) is utilized to assess the therapeutic efficacy of interventional therapy in liver cancer patients, offering insights into tumor blood flow changes, angiogenesis, and tumor markers.
aimTo evaluate the use of CEUS in examining the effectiveness of interventional therapy for liver cancer, we aim to investigate its diagnostic utility for tumor perfusion patterns, microvessel density, perfusion recovery, blood flow enhancement response, and alterations in tumor markers among patients receiving interventional therapy for liver cancer.
methodsThe study involved 124 patients who underwent interventional therapy for liver cancer at Guangzhou First People's Hospital from January 2022 to February 2024. All patients were examined using CEUS before treatment and at 1 month, 3 months, and 6 months, and the concentrations of tumor markers were collected and statistically analyzed using Statistical Package for the Social Sciences 25.0. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic efficacy of CEUS and analyze its sensitivity, specificity, and correlation with clinical indicators.
resultsBefore treatment, tumor blood flow was primarily enhanced. After treatment, enhanced perfusion declined, while uniform and non-uniform perfusion increased, indicating reduced tumor activity. Enhanced perfusion decreased from 68.25% before treatment to 53.75% at 6 months post-treatment (
conclusionCEUS has high diagnostic value in evaluating therapeutic effects in patients with liver cancer following interventional therapy. It can reflect changes in tumor blood flow, angiogenesis, and tumor marker levels, providing an effective basis for real-time monitoring of treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.